Tegsedi
(inotersen)Phase 3RNA therapy
Tegsedi is one of 52 small molecule programs targeting Cardiomyopathy. It is currently in Phase 3.
2
Indications
6
Total Trials
1
Active Trials
51
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
91 competitors in Cardiomyopathy
#DrugCompanyPhaseTrials
1Dobutrex
Eli LillyPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Wainua (autoinjector)
AstraZenecaPhase 3
Immunoglobulins
CSL BehringPhase 3
Cialis
Eli LillyPhase 2
Aldactone
PfizerPhase 2
Cellcept
RochePhase 2
Betaseron
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Polyneuropathy3 trials
Cardiomyopathy1 trial
24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
Terminated·—·Phase 2·NCT03702829·31 enrolled
Regulatory
FDA Approval Timeline[4]
Oct 5, 2018
TEGSEDI
NDA NDA211172
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for inotersen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]